SMS Pharmaceuticals Reports Q2 Net Profit of ₹39.1 Crore vs ₹25.1 Crore YoY

Market snapshot: SMS Pharmaceuticals Limited announced its standalone financial results for the second quarter ended September 30, 2026. Standalone net profit rose 55.78% YoY to ₹39.1 crore, while revenue from operations expanded 33.33% YoY to ₹320 crore.

Data Snapshot

• Q2 Standalone Net Profit reached ₹39.1 crore, representing a 55.78% YoY increase from ₹25.1 crore.
• Q2 Standalone Revenue from Operations expanded to ₹320 crore, registering a 33.33% YoY increase from ₹240 crore.

What's Changed

• Standalone net profit increased to ₹39.1 crore compared to ₹25.1 crore in the year-ago period.
• Quarterly standalone revenue expanded to ₹320 crore from ₹240 crore in Q2 of the previous fiscal year.

Key Takeaways

• Strong operational performance drove top-line revenue growth of 33.33% YoY to ₹320 crore.
• Net profit margin expansion resulted in a 55.78% YoY surge in quarterly profit to ₹39.1 crore.
• Operational leverage and consistent demand for core API products supported earnings trajectory.

SAHI Perspective

The acceleration in both top-line revenue and bottom-line profit highlights operational efficiency and margin strength in SMS Pharmaceuticals' core API business. The 55.78% YoY increase in net profit outpaced revenue growth, indicating effective cost management and favorable product mix shifts during the quarter.

Market Implications

Strong financial metrics reinforce investor sentiment around API manufacturing plays benefiting from operational scaling. The quarterly expansion reflects resilient demand across key pharmaceutical intermediates.

Trading Signals

Market Bias: Bullish

Robust YoY growth with standalone net profit expanding 55.78% to ₹39.1 crore and top-line revenue rising 33.33% to ₹320 crore supports positive directional sentiment for SMS Pharmaceuticals.

Overweight: Pharmaceuticals, Active Pharmaceutical Ingredients (APIs)

Trigger Factors:

• Earnings conference call management commentary on November 5, 2026
• Capacity utilization trends across Bachupally and Vizag manufacturing units

Time Horizon: Near-term (0-3 months)

Industry Context

Indian active pharmaceutical ingredient manufacturers continue to capture demand opportunities through product portfolio expansion and strategic backward integration.

Key Risks to Watch

• Raw material cost volatility affecting operating margins
• Regulatory compliance dynamics across key export jurisdictions

Recent Developments

SMS Pharmaceuticals scheduled its Q2 earnings conference call for November 5, 2026, to discuss financial results and operational performance.

Closing Insight

Consistent earnings growth alongside revenue expansion positions SMS Pharmaceuticals favorably within the API sector, provided operational margins remain stable.

High Performance Trading with SAHI.